RDY
Dr. Reddy's Laboratories Limited American Depositary Shares
Pharmaceutical Preparations
Best Pharmaceutical Stocks 2026 →
Dr. Reddy's Laboratories (RDY) Stock: Buy, Sell, or Hold?
$14.74
+0.01 (+0.07%)
▲
5d:
-1.14%
30d:
+14.26%
90d:
+21.72%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (27%)
Quality Score
33/100
Position
EXTENDED
30-Day Fair Range
$12.72 – $14.54
Position: EXTENDED
Forward P/E & Valuation
0.3x
FAIR
vs 0.3x historical avg
Wall Street Target
$14.41
-2.3% vs target
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$14.05 / $15.08
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: RDY shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When RDY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$13.99
Based on -2.0% avg growth
INTRINSIC VALUE TODAY
$8.68
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 0.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RDY is currently trading at $14.74, which is considered extended relative to its 30-day fair value range of $12.72 to $14.54. The stock's valuation (Forward PE: 0.3) is in line with its historical norms (0.3). At these levels, the market is pricing in 3.0% annual earnings growth.
Technical Outlook: Technically, RDY is in a downtrend. The price is approaching resistance at $15.08. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RDY scores 17/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RDY is in a downtrend. The price is approaching resistance at $15.08. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RDY scores 17/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$12.72 -
$14.54
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
27.1%
Trading Range & Key Levels
30-Day Trading Range
$12.72 -
$14.54
Current vs Trading Range
EXTENDED
Support Level
$14.05
Resistance Level
$15.08
Current Trend
Downtrend
Technical data as of
Nov 13, 2026
Quantitative Signal Breakdown
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (17/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($14.41)
- BULLISH: Expecting earnings turnaround to 3.0% growth with -1.5% revenue growth
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
0.28
Wall Street Target
$14.41
(-2.3%)
Revenue Growth (YoY)
-1.5%
Earnings Growth (YoY)
-35.7%
Profit Margin
8.5%
Valuation Premium vs History
+3.0% premium
PE vs Historical
0.3 vs 0.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.0%
(market-implied from PE analysis)
1-Year Target
$15.18
(+3%)
2-Year Target
$15.64
(+6%)
3-Year Target
$16.11
(+9%)
3-Yr Target (if PE normalizes)
(PE: 0→0)
$16.99
(+15%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: -8.0%)
$801.22
(+5336%)
Base:
(SPY PE: 0.3, Growth: -8.0%)
$11.48
(-22%)
Bear:
(PE: 0.2, Growth: -8.0%)
$9.75
(-34%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (41x PE), but valuation improves significantly next year (0x PE) as earnings recover.
Trailing PE: 41.03 | Current EPS (TTM): $0.36
Bull Case
$32.49
(+120%)
Analyst growth 100.0%, PE expands to 45.1
Base Case
$29.54
(+100%)
Market implied 100.0%, PE stable at 41.0
Bear Case
$10.04
(-32%)
Severe decline -20.0%, PE contracts to 34.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share RDY Analysis
Share this live RDY analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (RDY)
Bearish
1 Retail Mentions
Reddit / WSB Comments
1
Bearish
Last Tracked
May 13, 2024
Daily AI digest
AI Retail Discussion Summary:
Reddit & WallStreetBets discussions on RDY are bearish (sentiment score +0.00) across 1 tracked comments.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 14, 2026 5:53 AM ET
Data refreshes hourly during market hours. Next update: 6:53 AM
Data refreshes hourly during market hours. Next update: 6:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RDY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 30 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 39 SELL |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
15 analysts |
$49 | 47 HOLD |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$43 | 55 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 59 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive RDY Research Pages
